COMMENTARY

Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine

Fidel Dominique Festin Ambat1 · Enrico Bentivegna1 · Paolo Martelletti1,2

Accepted: 7 April 2022 / Published online: 16 May 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract
The introduction of new drug classes for migraine, such as monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) or its receptor and small-molecule antagonists of CGRP, have opened a new scenario in a large population of individuals suffering from migraines. The provision of an effective and safe therapy can help overcome the high social and personal costs together with the burden of this disease by offering social, work and economic recovery to the people affected by migraine. Whether the satisfaction of personal and collective unmet needs will be achieved in the vast majority of migraine sufferers now depends only on the efficiency of the organizational care structures dedicated to this socially impactful disease. This path will offer personal benefits and significant psychosocial relief that will help to reduce the enormous current healthcare expenditure necessary for the management of the huge number of individuals suffering from migraines. The new pharmacological classes for prevention must be applied as an interdiction to the chronic phase to express their full rehabilitation potential.

Around 12% of the global population have migraines, summing up to almost a billion patients. Those with the chronic form, about 2–3% of patients, face the highest direct and indirect costs of the disease. Direct costs primarily stem from frequent consultations, therefore more frequent hospital visits, coupled with greater inappropriate diagnostic exams and prescription drug use, while indirect costs arise from social isolation and failed job opportunities [1–5].

The cost of migraine is growing and will continue to grow, as a result of intense education campaigns revealing previously undiagnosed clinical situations and the availability of new pharmacological classes with proven safety and efficacy, as reviewed in the article by Cohen et al. in this issue of BioDrugs [6, 7].

The recent introduction of preventive drugs engineered against calcitonin gene-related peptide (CGRP), including monoclonal antibodies to the CGRP itself or its receptor, and CGRP antagonists, has benefited only a minority of these patients with high-frequency or chronic migraine, with prevention of pharmacological resistance or refractoriness opening up for them a health, social and productivity perspective not possible and imagined before with the existing standard of care (SOC) [8, 9].

This natural and progressive evolution of individuals with migraine towards chronicity or drug resistance and refractoriness is nowadays efficaciously reversed by using CGRP(r) monoclonal antibodies, rightly defined as disease-modifying migraine drugs [10].

The question we must face today, beyond the indisputable universal and ethical-social value of public health in Europe, is whether or not national health systems can bear the costs of these innovative therapies on the basis of parameters that go beyond the concept of savings, combined with the distributive equity of health resources to ensure the satisfaction of unmet needs in the field of public health dedicated to chronic diseases [11–13].

Chronic migraine must also be considered as one of the various chronic diseases that can occur in the same individual, in a comorbid way or by simple co-occurrence, e.g. comorbid migraine with depression or obesity, and co-occurrence with asthma, diabetes or other diseases [14]. In this context, it should also be considered that the coexistence in the same individual of several comorbid chronic diseases that are not adequately treated favours the concept of the irreversibility of the chronicity trend with all that follows—burden, disability, cost and job inequalities [3, 15, 16].
We should furthermore consider the necessary but disproportionate health care disparity that has arisen with the coronavirus disease 2019 (COVID-19) pandemic, penalizing the management of chronic diseases, including migraines. This situation is now progressively recovering through the application of new healthcare approaches [17].

The immense direct and indirect costs associated with chronic migraine have already been mentioned. Taking a closer look, direct costs are related to prescriptions, diagnostic examinations, access to emergency departments, products and services, while indirect costs are related to the effects that chronic migraine has in other aspects of life such as mobility, employment, social and emotional well-being [3–5, 18]. Since prescription drug costs are significantly higher for chronic migraine sufferers, and SOC often leads to multiple prescriptions with the danger of harmful interactions [19], changing treatment practices to choosing the novel preventative drug classes (CGRP\(_{\alpha}\) monoclonal antibodies or gepants) could significantly improve treatment adherence, reduce the complications and, therefore, costs [20–22]

The disabilities associated with, and the monitoring required for, chronic migraine can be socially debilitating for many. Chronic mental and physical conditions can lead to harmful degrees of social isolation. Acute drug overuse resulting from the poor efficacy of SOC may lead the individual with migraine to a situation of improper use of acute drugs, often resulting in the development of dependence on them [23]. Also, the use of combination/add-on therapy could become redundant and, therefore, be eliminated in favour of the new-generation, innovative drugs [24].

The costs of these new drugs can be considered high in principle when compared with SOC. However, if considered in the light of their effectiveness in reducing the frequency and intensity of crises and in improving the overall economic, personal and social framework and productivity of the individual, it can rightly be seen as an opportunity for rehabilitation from a chronic disease, together with an overall saving in economic terms. These assumptions should favour the sustainability of these innovative therapies in an increasingly large proportion of migraine sufferers.

On the basis of these human and social considerations and economic evidence, a non-restrictive application of the new migraine prevention drugs must be hypothesized, considering their use as a first-line treatment in patients who present a consolidated progression towards the chronic phase, so as to compensate for the greater expense needed for their care with increased work productivity, resulting in a net reduction in general health costs previously incurred by the community as a whole and by people with migraine [25].

Finally, intercepting the chronic phase and preventing the evolution to resistance/refractoriness of migraine can generate a sort of social and personal economic added value. This, while guaranteeing the well-being of people with migraine, leads to the passing of those silent barriers that are intrinsic to any public health system based on universality [26].

Declarations

Funding No funding was received for the preparation of this manuscript.

Conflict of interest The authors disclose no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.

Author contributions All authors contributed equally to the writing of this commentary, and approved the final version.

Ethics approval Not applicable.

Consent to participate/publish Not applicable.

Availability of data and material Not applicable.

Code availability Not applicable.

References

1. Thomas H, Kothari SF, Husøy A, et al. The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries. J Headache Pain. 2021;22:153. https://doi.org/10.1186/s10194-021-01362-z.

2. Obermeier V, Murawski M, Heinen F, Landgraf MN, Straube A, von Kries R, Ruscheweyh R. Total health insurance costs in children with a migraine diagnosis compared to a control group. J Headache Pain. 2021;22(1):140. https://doi.org/10.1186/s10194-021-01349-w.

3. Wong LP, Alias H, Bhoo-Pathy N, Chung I, Chong YC, Kalra S, Shah ZUBS. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. J Headache Pain. 2020;21(1):68. https://doi.org/10.1186/s10194-020-01144-z (Erratum in: J Headache Pain. 2020 Aug 18;21(1):104).

4. Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, Azuma Y, Dodick DW. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29. https://doi.org/10.1186/s10194-021-01243-5.

5. Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110. https://doi.org/10.1186/s10194-020-01180-9.

6. Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022;1–18. https://doi.org/10.1007/s40259-022-00530-0.

7. Vandervorst F, Van Deun L, Van Dycke A, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22:128. https://doi.org/10.1186/s10194-021-01335-2.
Impact of Novel Migraine Therapies

8. Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain. 2020;21:76. https://doi.org/10.1186/s10194-020-01130-5.

9. Sacco S, Lamp C, Maassen van den Brink A, et al. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain. 2021;22:39. https://doi.org/10.1186/s10194-021-01252-4.

10. Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDS). J Headache Pain. 2019;20:60. https://doi.org/10.1186/s10194-019-1009-9.

11. Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Tiwari S, Joshi P, Ferrari M. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 2021;24(1):900–7. https://doi.org/10.1080/13696998.2021.1953301.

12. Steiner TJ, Linde M, Schnell-Inderst P. A universal outcome measure for headache treatments, care-delivery systems and economic analysis. J Headache Pain. 2021;22(1):63. https://doi.org/10.1186/s10194-021-01269-9.

13. Martelletti P, Schwedt TJ, Vo P, Ritrovato D, Reilly MC, Naclerio M, Ranjan P, Kleebach J, Joshi P. Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ. 2021;24(1):717–26. https://doi.org/10.1080/13696998.2021.1925557.

14. Caponnetto V, Deodato M, Robotti M, et al. Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain. 2021;22:71. https://doi.org/10.1186/s10194-021-01281-x.

15. Yu S, Zhang Y, Yao Y, Cao H. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 2020;21(1):53. https://doi.org/10.1186/s10194-020-01117-2.

16. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain. 2019;20(1):41. https://doi.org/10.1186/s10194-019-0993-0.

17. Bentivegna E, Tassorelli C, De Icco R, Sances G, Martelletti P. Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Rev Neurother. 2022. https://doi.org/10.1080/14737157.2022.2045954.

18. Negro A, Spuntarelli V, Sciattella P, Martelletti P. Rapid referral for headache management from emergency department to headache centre: four years data. J Headache Pain. 2020;21(1):25. https://doi.org/10.1186/s10194-020-01094-6.

19. Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120. https://doi.org/10.1186/s10194-019-1068-y.

20. McAllister P, Lamertao L, Krasenbaum LJ, Cohen JM, Tangiral K, Thompson S, Diessen M, Casciano J, Dottiwala Z, Mauskop A. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22(1):156. https://doi.org/10.1186/s10194-021-01358-9.

21. Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d’Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):154. https://doi.org/10.1186/s10194-021-01363-y.

22. Foster SA, Hoyt M, Ye W, Mason O, Ford JH. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Curr Med Res Opin. 2021;2:1–8. https://doi.org/10.1080/03007995.2021.2001127.

23. Takahashi TT, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S, Guglielmetti M, Maria De Marco C, Dutordoic C, Colangeli E, Fuccaro M, Di Lenola D, Spuntarelli V, Pilati L, Di Marco S, Van Dycke A, Abdullaha RA, Maassen van den Brink A, Martelletti P, European Headache Federation School of Advanced Studies (EHF-SAS). Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain. 2021;22(1):32. doi: https://doi.org/10.1186/s10194-021-01224-8. Erratum in: J Headache Pain. 2021 Jul 5;22(1):64.

24. Martelletti P, Luciani M, Spuntarelli V, Bentivegna E, Deprescribing in migraine. Expert Opin Drug Saf. 2021;20(6):623–5. https://doi.org/10.1080/14740338.2021.1907342.

25. Benemei S, Bentivegna E, Martelletti P. Positioning the new drugs for migraine. Expert Opin Drug Metab Toxicol. 2022. https://doi.org/10.1080/17425255.2022.2049236.

26. Tinelli M, Leonardi M, Paemeleire K, Raggi A, Mitsikostas D, de la Torre ER, Steiner TJ, European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Migraine and Headache Alliance and Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22(1):90. https://doi.org/10.1186/s10194-021-01305-8.